Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 15/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 15/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25996566 | 1.00 | CYP4F2 (0.35) | CYP4F2CYP4A11TBXAS1 | |
| SCHEMBL25996564 | 1.00 | CYP4F2 (0.35) | CYP4F2CYP4A11TBXAS1 | |
| SCHEMBL25996569 | 1.00 | CYP4F2 (0.35) | CYP4F2CYP4A11TBXAS1 | |
| SCHEMBL25996565 | 1.00 | CYP4F2 (0.35) | CYP4F2CYP4A11TBXAS1 | |
| SCHEMBL25996568 | 1.00 | CYP4F2 (0.35) | CYP4F2CYP4A11TBXAS1 | |
| SCHEMBL25996562 | 0.99 | CYP4F2 (0.34) | CYP4F2CYP4A11TBXAS1 | |
| SCHEMBL25996559 | 0.98 | CYP4F2 (0.34) | CYP4F2CYP4A11TBXAS1 | |
| SCHEMBL25996557 | 0.97 | CYP4F2 (0.33) | CYP4F2CYP4A11TBXAS1 | |
| SCHEMBL25996560 | 0.96 | CYP4F2 (0.32) | CYP4F2CYP4A11TBXAS1 | |
| SCHEMBL25996556 | 0.94 | TBXAS1 (0.30) | CYP4F2CYP4A11TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | AHR, PKD1, CFTR | CYP4F2 687/4885CYP4A11 605/4885TBXAS1 3787/4885 |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | CPT1A, PPARG, PC | CYP4F2 674/4885CYP4A11 642/4885TBXAS1 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.